KRRO Korro Bio, Inc.
Price Chart
Executive Summary
Korro Bio selected KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), a genetic disease affecting ~3.4 million people worldwide. Preclinical data showed >90% SERPINA1 RNA editing and ~90% functional M-AAT protein in a mouse model, plus near-elimination of pathogenic Z-protein production. The company also reiterated its cash runway into H2 2028 ($157.1M as of March 31, 2026), a planned regulatory filing for KRRO-121 in H2 2026, and a third GalNAc-liver asset development candidate expected in H2 2026.
Actionable Insight
KRRO-111's best-in-class preclinical profile adds pipeline optionality to the OPERA platform thesis and may attract partnership interest. Monitor KRRO-121 regulatory filing in H2 2026 as the next major catalyst; also watch for third liver asset nomination and eventual Phase 1 data readouts from both programs.
Key Facts
- KRRO-111 selected as development candidate for AATD; demonstrated >90% SERPINA1 RNA editing and ~90% M-AAT protein in vivo
- Repeat-dose study (3 mg/kg Q2W) showed near-elimination of active Z-protein (~95% reduction vs vehicle) and progressive clearance of pre-existing aggregates (~69% reduction at day 28)
- Cash, cash equivalents, and marketable securities of $157.1M as of March 31, 2026; cash runway into H2 2028
- Regulatory filing for KRRO-121 (urea cycle disorders) anticipated in H2 2026
- Third GalNAc-conjugated liver asset development candidate expected in H2 2026
- Potential for partnership across pipeline noted in corporate presentation
Financial Impact
No financial terms disclosed; $157.1M cash runway into H2 2028 supports both KRRO-111 and KRRO-121 clinical programs
Risk Factors
- All data are preclinical; clinical translation is not guaranteed
- AATD is a competitive space with existing augmentation therapy and other RNA-based approaches in development
- Korro is pre-revenue with no approved products; reliance on capital markets for funding
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-229610 |
| Document: krro-ex99_1.htm | 0001193125-26-229610 |
| Document: krro-ex99_2.htm | 0001193125-26-229610 |
| Document: 0001193125-26-229610-index-headers.html | 0001193125-26-229610 |
| Document: 0001193125-26-229610-index.html | 0001193125-26-229610 |
| Document: 0001193125-26-229610.txt | 0001193125-26-229610 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $10.62 awaiting T+1 | awaiting T+1 | — | $11.61 (+9.37%) |
|
Jun 2, 2026
12d ago
|
Insider Cluster
| $11.00 $11.08 | ▲ +0.73% | ▲ +1.45% | $11.61 (+5.55%) |
|
May 19, 2026
26d ago
|
8-K
| $9.15 $10.01 | ▲ +9.40% | ▲ +8.36% | $11.61 (+26.89%) |
|
Apr 16, 2026
8w ago
|
DEFA14A
| $13.47 $14.39 | ▲ +6.83% | ▲ +5.62% | $11.61 (−13.81%) |
|
Mar 23, 2026
12w ago
|
EFFECT
| $11.27 $10.58 | ▼ −6.12% | ▼ −5.77% | $11.61 (+3.02%) |
|
Mar 13, 2026
13w ago
|
S-3
| $12.60 $12.31 | ▲ +2.30% | ▲ +2.57% | $11.61 (+7.86%) |
|
Mar 10, 2026
13w ago
|
Insider Cluster
| $11.48 $11.76 | ▲ +2.44% | ▲ +2.54% | $11.61 (+1.13%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $12.30 $11.48 | ▼ −6.67% | ▼ −6.48% | $11.61 (−5.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access